[i] American Cancer Society. Key statistics for lung cancer. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html. Accessed October 10, 2018.
[ii] Lung Cancer Foundation of America. What is ALK Positive Lung Cancer? And what are the options for treatment?. https://lcfamerica.org/research-grants/therapies/alk-positive-lung-cancer/. Accessed October 26, 2018.
[iii] American Cancer Society. What is non-small cell lung cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed October 3, 2018
[iv] American Cancer Society. Lung cancer (non-small cell) detailed guide. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html. Accessed October 3, 2018.
[v] The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). (2013). A genomics-based classification of human lung tumors. Science Translational Medicine, 5(209), 209ra153.
[vi] American Cancer Society. (August 8, 2016). What is cancer immunotherapy? https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/what-is-immunotherapy.html. Accessed October 11, 2018
[vii] Roth, J.A., Goulart, B.J., Ravelo, A., Kolkey, H., & Ramsey, S.D. (2017). Survival gains from first-line systemic therapy in metastatic non-small cell lung cancer in the U.S., 1990-2015: Progress and opportunities. Oncologist (22)3: 304-310.